In this multicenter, single‐arm trial, we investigated the efficacy and safety of the ECPy‐THPy regimen (epirubicin, cyclophosphamide, and pyrotinib followed by docetaxel, trastuzumab, and pyrotinib) as neoadjuvant therapy for patients with stage II–III HER2‐positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.